C
온코닉테라퓨틱스
476060KOSDAQ52.5 / 100
Reference Date: 2026-10-23
Financial Score25.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 11.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Onconic Therapeutics focuses on developing innovative drugs for unmet medical needs in gastroesophageal reflux disease and oncology, emphasizing cost-effective small-molecule compounds. Its key product, 'Zastaprazan,' a P-CAB mechanism drug, has completed Phase 3 trials and received approval, while its next-generation oncology candidate 'Nesuparib' is in various clinical trials.
Number of Employees
38people
Average Salary
78.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
35.99Industry Average 15.000.0Point
2.4x industry avg (risky)
PBR
8.14Industry Average 1.200.0Point
6.8x industry avg (risky)
ROE
24.65Industry Average 8.007.0Point
3.1x industry avg (excellent)
Debt Ratio
0.06Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2024~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲259.8% (1-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲363.0% (1-year basis)
ROE Trend
4.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (20%)
Current 12,920Won52-week high 26,30052-week low 9,510
1-month return1.0Point
1m -11.32% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral의결권대리행사권유참고서류2026-10-16
- Neutral주주총회소집공고2026-10-16
- Neutral주주총회소집결의 (임시주주총회)2026-10-16
- Neutral주주명부폐쇄기간또는기준일설정2026-10-16